Over 80 genetic markers that can increase the risk of developing breast, prostate or ovarian cancer have been found in the largest study of its kind, which involved 200,000 people. The DNA of the test subjects, half of whom had cancer while the other half did not, was compared to reveal an individual's inherited risk of the diseases. British scientists, who led the research, believe it could lead to a DNA screening test within five years.
The research was led by scientists at the University of Cambridge, and the Institute of Cancer Research (ICR) in London and funded by Cancer Research UK (CRUK) and the Welcome Trust. The main findings of the research are published in five articles in the journal Nature Genetics.
Study author Professor Doug Easton said: "We're on the verge of being able to use our knowledge of these genetic variations to develop a test that could complement breast cancer screening and take us a step closer to having an effective prostate cancer screening programme."
The scientists were looking for common genetic variations - known as single nucleotide polymorphisms (Snps) - linked to the three cancers. Each alteration they found increased the patient's risk of cancer by a small amount, but a small minority of men with lots of the markers could see their risk of prostate cancer increase more than fourfold, and for women the breast cancer risk increased threefold.
The test could also help the one in 300 women who carry a faulty gene known as BRCA1 or BRCA2. Two thirds of them will develop breast cancer before the age of 80 and 45% who carry BRCA1 will get ovarian cancer. By combining the gene test for BRCA1 and BRCA2 with this extra genetic information, women who have a high number of the newly identified markers could find they have nearly a 100% risk of getting breast cancer. In contrast, those with the protective versions of the genetic changes could see their risk drop to as little as 20%.
Dr Antonis Antoniou, CRUK senior fellow at the University of Cambridge, said: "Our research puts us on the verge of being able to give women a much more accurate picture of how likely they are to develop breast or ovarian cancer and would help to guide them about the most appropriate type and time of prevention or monitoring options for them."
The research also sheds light on the risk of prostate cancer in men, which unlike breast cancer does not currently have a screening programme. The average lifetime risk of a man developing prostate cancer is one in eight, but for the 1% who carry a significant number of genetic alterations, the risk rises to one in two. Sixteen of the 23 newly identified genetic markers are associated with aggressive forms of the disease so may help clinicians and patients decide on the best form of treatment. Prof Ros Eles, from the ICR, said: "These results are the single biggest leap forward in finding the genetic causes of prostate cancer." He went on to say: "If further studies show such men benefit from regular screening, we could have a big impact on the number of people dying from the disease, which is still far too high."
Jack
Saturday, 30 March 2013
Saturday, 23 March 2013
Scientists identify gene fault with "domino effect" on cancer risk
Scientists have identified a brand new genetic mechanism that raises the risk of cancer via a domino effect on DNA - with one gene fault triggering a second, cancer-causing mutation. The team, from The Institute of Cancer Research, London, found that some cancer patients inherit a weak point in their DNA which appears to leave one of their chromosomes vulnerable to snapping and becoming mutated.
The researchers hailed the finding, which was published in Nature Genetics, as a "very important discovery" that opens up new avenues for cancer treatment and prevention. The study sheds new light on the causes of multiple myeloma, a type of blood cancer, which affects around 4,700 patients in the UK each year - and could have implications for other types of cancer. It is the first time scientists have found evidence that inheritance of a gene fault can increase the risk of suffering a specific chromosomal mutation - in this case one that can drive development of cancer.
In the study, which was funded by a number of organisations, the DNA of 1,655 patients with myeloma was assessed and compared with people in the general population. This was to explore whether the patients had inherited genetic faults which had increased their risk of developing the disease. They then found that inheritance of a specific DNA range termed CCND1 G870A was associated with an 80% increase in the risk of developing a sub-type of myeloma affecting about a fifth of patients. This sub-type is known to be triggered by a specific chromosomal translocation (a type of DNA breakage and rearrangement) designated by the code t(11;14). The translocation forms a mutant piece of DNA that drives cancer by activating several genes.
Study author Professor Richard Houlston, Professor of Molecular and Population Genetics at the Institute of Cancer Research, said: "It's the first time anyone has identified a specific gene fault that raises the risk of developing a second specific type of DNA damage. Not only is the discovery valuable for our understanding of multiple myeloma, but it also demonstrates the value of studying specific genetic sub-types of cancer, rather than grouping them all together as one disease." Co-author Professor Gareth Morgan, Head of Molecular Haematology at the Institute of Cancer Research and Head of the Myeloma Unit at The Royal Marsden, also commented: "This is a very important discovery, which opens out our understanding of cancer genetics and gives us new avenues for treatment and prevention." He continued to say: "Now that we have found a genetic risk factor for a particular sub-type of multiple myeloma, I'm hopeful we can design more targeted treatments for the people who develop it. In cancer research we tend to group different sub-types together, but this research proves that we need to move away from this approach and investigate sub-types at a molecular level."
Jack
The researchers hailed the finding, which was published in Nature Genetics, as a "very important discovery" that opens up new avenues for cancer treatment and prevention. The study sheds new light on the causes of multiple myeloma, a type of blood cancer, which affects around 4,700 patients in the UK each year - and could have implications for other types of cancer. It is the first time scientists have found evidence that inheritance of a gene fault can increase the risk of suffering a specific chromosomal mutation - in this case one that can drive development of cancer.
In the study, which was funded by a number of organisations, the DNA of 1,655 patients with myeloma was assessed and compared with people in the general population. This was to explore whether the patients had inherited genetic faults which had increased their risk of developing the disease. They then found that inheritance of a specific DNA range termed CCND1 G870A was associated with an 80% increase in the risk of developing a sub-type of myeloma affecting about a fifth of patients. This sub-type is known to be triggered by a specific chromosomal translocation (a type of DNA breakage and rearrangement) designated by the code t(11;14). The translocation forms a mutant piece of DNA that drives cancer by activating several genes.
Study author Professor Richard Houlston, Professor of Molecular and Population Genetics at the Institute of Cancer Research, said: "It's the first time anyone has identified a specific gene fault that raises the risk of developing a second specific type of DNA damage. Not only is the discovery valuable for our understanding of multiple myeloma, but it also demonstrates the value of studying specific genetic sub-types of cancer, rather than grouping them all together as one disease." Co-author Professor Gareth Morgan, Head of Molecular Haematology at the Institute of Cancer Research and Head of the Myeloma Unit at The Royal Marsden, also commented: "This is a very important discovery, which opens out our understanding of cancer genetics and gives us new avenues for treatment and prevention." He continued to say: "Now that we have found a genetic risk factor for a particular sub-type of multiple myeloma, I'm hopeful we can design more targeted treatments for the people who develop it. In cancer research we tend to group different sub-types together, but this research proves that we need to move away from this approach and investigate sub-types at a molecular level."
Jack
Saturday, 16 March 2013
Early HIV drugs could functionally cure around 10%
According to researchers in France, rapid treatment after HIV infection may be enough to "functionally cure" about a 10th of those diagnosed early. They reached this conclusion after having analysed 14 people who stopped therapy, but have since shown no signs of the virus resurging.
The group of 14 patients, known as the Visconti cohort, all started treatment within 10 weeks of being infected. These patients were able to be diagnosed early as they turned up in hospital with other conditions and HIV was found in their blood. The patients each stuck to a course of antiretroviral drugs for 3 years on average, but then stopped taking them; the drugs are only able to keep the virus in check and unable to completely eradicate it from its hiding places within the immune system. Therefore, when treatment stops, the virus is expected to bounce back, but in the case of the Visconti patients this did not happen.
Dr Asier Saez-Cirion, from the institute Pasteur in Paris, said: "Most individuals who follow the same treatment will not control the infection, but there are a few of them who will." He said that 5-15% of patients may be functionally cured by attacking the virus soon after infection, meaning they would no longer require drugs. This patients would still have HIV, as the virus is not completely eradicated, but it is a kind of remission of the infection.
The researchers' latest study, which can be found in the journal PLoS Pathogens, analysed what happened to the immune system of the patients. It is now understood that early treatment may limit the number of unassailable HIV hideouts that are formed, but it is "unclear" why only some patients were functionally cured. Dr Andrew Freedman, a reader in infectious diseases at Cardiff University School of Medicine, said the findings were "certainly interesting". He went on to say: "The presumption is that they've started treatment very early and the virus hasn't spread to so many of the long-term reservoirs and that's why it works. Whether they'll control it forever, or whether it'll be for a number of years and subsequently they will progress and the virus will reappear, we don't know." Deborah Jack, the chief executive of the National AIDS Trust said it was "exciting times" in progress towards a HIV cure, but the key was early treatment.
Jack
The group of 14 patients, known as the Visconti cohort, all started treatment within 10 weeks of being infected. These patients were able to be diagnosed early as they turned up in hospital with other conditions and HIV was found in their blood. The patients each stuck to a course of antiretroviral drugs for 3 years on average, but then stopped taking them; the drugs are only able to keep the virus in check and unable to completely eradicate it from its hiding places within the immune system. Therefore, when treatment stops, the virus is expected to bounce back, but in the case of the Visconti patients this did not happen.
Dr Asier Saez-Cirion, from the institute Pasteur in Paris, said: "Most individuals who follow the same treatment will not control the infection, but there are a few of them who will." He said that 5-15% of patients may be functionally cured by attacking the virus soon after infection, meaning they would no longer require drugs. This patients would still have HIV, as the virus is not completely eradicated, but it is a kind of remission of the infection.
The researchers' latest study, which can be found in the journal PLoS Pathogens, analysed what happened to the immune system of the patients. It is now understood that early treatment may limit the number of unassailable HIV hideouts that are formed, but it is "unclear" why only some patients were functionally cured. Dr Andrew Freedman, a reader in infectious diseases at Cardiff University School of Medicine, said the findings were "certainly interesting". He went on to say: "The presumption is that they've started treatment very early and the virus hasn't spread to so many of the long-term reservoirs and that's why it works. Whether they'll control it forever, or whether it'll be for a number of years and subsequently they will progress and the virus will reappear, we don't know." Deborah Jack, the chief executive of the National AIDS Trust said it was "exciting times" in progress towards a HIV cure, but the key was early treatment.
Jack
Friday, 8 March 2013
Baby 'cured' of HIV by early drug treatment
A baby girl in the US, who was born with HIV, appears to have been cured by very early treatment with standard drug therapy. The child is now two-and-a-half years old and has been off medication for about a year with no signs of infection.
If the girl stays healthy it would be the world's second reported 'cure', after Timothy Ray Brown who was the first person to recover from HIV in 2007. His infection was eradicated using an elaborate treatment for leukaemia that involved the destruction of his immune system, followed by a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection. In contrast to this, the case of the US baby involved a cocktail of widely available drugs, known as antiretroviral therapy, already used to treat HIV infection in infants. This suggests that the swift treatment wiped out HIV before it could form hideouts in the body.
The baby was born in a rural hospital but was then transferred to the University of Mississippi Medical Center in Jackson. Once there, paediatric specialist Dr Hannah Gay put the infant on a cocktail of three standard HIV-fighting drugs at just 30 hours old, even before laboratory tests came back confirming the infection. The treatment continued for 18 months, at which point the child disappeared into the medical system. Five months later the mother and child turned up again but had stopped the treatment in this interim; the doctors then carried out tests to see if the virus had returned and were astonished to discover that it had not.
Dr Rowena Johnston, of the foundation for Aids Research, said it appeared that the early intervention by Dr Hannah Gay had worked, and praised the work as "very exciting". She also described how many doctors in six different laboratories had all applied different, very sophisticated tests trying to find HIV in the infant and none were able to find any. This led her to say: "We really can quite confidently conclude at this point that the child does very much appear to be cured." A spokeswoman for the HIV/Aids charity the Terrence Higgins Trust also commented: "This is interesting, but the patient will need careful ongoing follow-up for us to understand the long-term implications for her and any potential for other babies born with HIV."
Jack
If the girl stays healthy it would be the world's second reported 'cure', after Timothy Ray Brown who was the first person to recover from HIV in 2007. His infection was eradicated using an elaborate treatment for leukaemia that involved the destruction of his immune system, followed by a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection. In contrast to this, the case of the US baby involved a cocktail of widely available drugs, known as antiretroviral therapy, already used to treat HIV infection in infants. This suggests that the swift treatment wiped out HIV before it could form hideouts in the body.
The baby was born in a rural hospital but was then transferred to the University of Mississippi Medical Center in Jackson. Once there, paediatric specialist Dr Hannah Gay put the infant on a cocktail of three standard HIV-fighting drugs at just 30 hours old, even before laboratory tests came back confirming the infection. The treatment continued for 18 months, at which point the child disappeared into the medical system. Five months later the mother and child turned up again but had stopped the treatment in this interim; the doctors then carried out tests to see if the virus had returned and were astonished to discover that it had not.
Dr Rowena Johnston, of the foundation for Aids Research, said it appeared that the early intervention by Dr Hannah Gay had worked, and praised the work as "very exciting". She also described how many doctors in six different laboratories had all applied different, very sophisticated tests trying to find HIV in the infant and none were able to find any. This led her to say: "We really can quite confidently conclude at this point that the child does very much appear to be cured." A spokeswoman for the HIV/Aids charity the Terrence Higgins Trust also commented: "This is interesting, but the patient will need careful ongoing follow-up for us to understand the long-term implications for her and any potential for other babies born with HIV."
Jack
Saturday, 2 March 2013
Cancers "shuffle their genetic pack" in order to resist treatment
It is already known that because of "chromosomal instability" cancer cells are able to "reshuffle" their chromosomes, thus increasing cell diversity in tumours. New research now reveals that if bowel cancer cells lack one of three genes they are able to carry out the genetic reshuffling very quickly. The researchers, led by Charles Swanton, a professor based at Cancer Research UK's London Research Institute and the UCL Cancer Institute, write about their findings in the online version of Nature.
Recent work carried out by Cancer Research UK and other groups shows that a tumour has a complex genetic landscape, and is beginning to change the way scientists understand the disease. One explanation for why this happens is that it increases the genetic diversity of the cancer cells, allowing them to adapt to new environments, spur tumour growth, or help resist treatment.
Swanton says that by uncovering how cancer cells manage to continually shuffle their genetic pack, it may be possible to turn their strength into a weakness, and create so much instability that the cells can't function normally and die. He went on to say: "We're now looking for ways in which this process can be targeted in order to tip cancer cells over the edge."
Normal cells have 46 chromosomes, but each time cancer cells divide they gain or lose whole or large fractions of chromosomes; this results in an imbalance in the number of chromosomes per cell (a state known as "aneuploidy"). Because of this, chromosomal instability is a defining characteristic of most human cancers. It also means that a tumour can contain cells of enormous genetic diversity, making them increasingly difficult to treat.
What Swanton and his colleagues found was that loss of any of three particular genes on a chromosome region known as 18q, interfered with the normal copying process, which led to mistakes in chromosome separation. By adding nucleotides to bowel cancer cells lacking all three of the genes, Swanton and colleagues found they could dramatically reduce chromosomal instability, and prevent further copying errors and the genetic shuffling.
Nic Jones, professor and chief scientist at Cancer Research UK, says it is not just in bowel cancer that 18q is missing, which perhaps suggests that this process is common to other types of cancer. He also said: "By understanding how cancer cheats at life's card-game, we can see how an individual person's cancer can be so complex and varied" and "Scientists can now start looking for ways to prevent this happening in the first place or turning this instability against cancers."
Jack
Recent work carried out by Cancer Research UK and other groups shows that a tumour has a complex genetic landscape, and is beginning to change the way scientists understand the disease. One explanation for why this happens is that it increases the genetic diversity of the cancer cells, allowing them to adapt to new environments, spur tumour growth, or help resist treatment.
Swanton says that by uncovering how cancer cells manage to continually shuffle their genetic pack, it may be possible to turn their strength into a weakness, and create so much instability that the cells can't function normally and die. He went on to say: "We're now looking for ways in which this process can be targeted in order to tip cancer cells over the edge."
Normal cells have 46 chromosomes, but each time cancer cells divide they gain or lose whole or large fractions of chromosomes; this results in an imbalance in the number of chromosomes per cell (a state known as "aneuploidy"). Because of this, chromosomal instability is a defining characteristic of most human cancers. It also means that a tumour can contain cells of enormous genetic diversity, making them increasingly difficult to treat.
What Swanton and his colleagues found was that loss of any of three particular genes on a chromosome region known as 18q, interfered with the normal copying process, which led to mistakes in chromosome separation. By adding nucleotides to bowel cancer cells lacking all three of the genes, Swanton and colleagues found they could dramatically reduce chromosomal instability, and prevent further copying errors and the genetic shuffling.
Nic Jones, professor and chief scientist at Cancer Research UK, says it is not just in bowel cancer that 18q is missing, which perhaps suggests that this process is common to other types of cancer. He also said: "By understanding how cancer cheats at life's card-game, we can see how an individual person's cancer can be so complex and varied" and "Scientists can now start looking for ways to prevent this happening in the first place or turning this instability against cancers."
Jack
Subscribe to:
Posts (Atom)